STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
64
13F, latest reported quarter
What the filings say about QSI
Insiders, 180 days
-$110.7K net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$39.4K
3 notices
Quantum-Si insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Quantum-Si Inc insiders sold a net $110.7K of stock across 79 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
16 earlier Form 4 trades (code P or S) here by this insider (4 buys, 12 sales), the last on Sep 21, 2026.
-10.9% median (-9.6% mean) 90-day return after 4 previous buys.
The trade is 0.4% of the 1,167,913 shares held after it.
2 other insiders sold within 30 days.
64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: GC & Corp. Secretary LaPointe Christian sold about $3.6K of QSI on Sep 22, 2026; 2 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
14 earlier Form 4 trades (code P or S) here by this insider (2 buys, 12 sales), the last on Sep 21, 2026.
-2.5% median (-2.5% mean) 90-day return after 2 previous buys.
The trade is 0.1% of the 1,716,684 shares held after it.
2 other insiders sold within 30 days.
64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Keyes Jeffry R. sold about $1.9K of QSI on Sep 22, 2026; 2 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
14 earlier Form 4 trades (code P or S) here by this insider (2 buys, 12 sales), the last on Sep 21, 2026.
-6.1% median (-6.1% mean) 90-day return after 2 previous buys.
The trade is 0.3% of the 3,639,950 shares held after it.
2 other insiders sold within 30 days.
64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Hawkins Jeffrey Alan sold about $7.4K of QSI on Sep 22, 2026; 2 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
15 earlier Form 4 trades (code P or S) here by this insider (4 buys, 11 sales), the last on Jun 23, 2026.
-10.9% median (-9.6% mean) 90-day return after 4 previous buys.
The trade is 0.8% of the 1,172,634 shares held after it.
2 other insiders sold within 30 days.
64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: GC & Corp. Secretary LaPointe Christian sold about $7.4K of QSI on Sep 21, 2026; 2 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
13 earlier Form 4 trades (code P or S) here by this insider (2 buys, 11 sales), the last on Jun 23, 2026.
-2.5% median (-2.5% mean) 90-day return after 2 previous buys.
The trade is 0.3% of the 1,719,177 shares held after it.
2 other insiders sold within 30 days.
64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Keyes Jeffry R. sold about $3.9K of QSI on Sep 21, 2026; 2 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
79 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Nobody has filed for crossing 5%. That is a fact, not missing data.
QSI planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Hawkins Jeffrey Alan
Filed 2026-09-23
$22.6K
Keyes Jeffry R.
Filed 2026-09-23
$5.8K
LaPointe Christian
Filed 2026-09-23
$11.0K
Hawkins Jeffrey Alan
Filed 2026-06-24
$21.0K
Keyes Jeffry R.
Filed 2026-06-24
$7.6K
QSI mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$4.8M position · as of 2026-07-31
0.3%
Ultra-Small Company Market Fund
$177.0K position · as of 2026-06-30
0.1%
Invesco Nasdaq Biotechnology ETF
$12.3K position · as of 2026-05-31
0.0%
VANGUARD RUSSELL 2000 VALUE INDEX FUND
$157.8K position · as of 2026-05-31
0.0%
ProShares Ultra Nasdaq Biotechnology
$8.6K position · as of 2026-05-31
0.0%
iShares Biotechnology ETF
$1.1M position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Jeffrey Hawkins
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.2M
-$2.9M
$1.6M
-40%
n/a
2024
$4.4M
$8.7M
$1.6M
+48%
n/a
2023
$1.1M
$1.9M
$1.3M
+10%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $110.7K sold by insiders over 180 days, 64 funds added last quarter, $39.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM QSI
FY Dec 2025
$2.4M
FY Dec 2024
$3.1M
FY Dec 2023
$1.1M
FY Dec 2022
$0
FY Dec 2021
n/a
Jun 2026
$344.0K
Mar 2026
$258.0K
Dec 2025
$451.0K
Sep 2025
$552.0K
Jun 2025
$591.0K
Mar 2025
$842.0K
Dec 2024
$1.2M
Sep 2024
$787.0K
At each fiscal year end
Single quarter
Net margin, TTM
-6,138%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM QSI
FY Dec 2025
-4,160%
FY Dec 2024
-3,303%
FY Dec 2023
-8,869%
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
-6,841%
Mar 2026
-8,400%
Dec 2025
-3,905%
Sep 2025
-6,468%
Jun 2025
-4,879%
Mar 2025
-2,279%
Dec 2024
-2,779%
Sep 2024
-3,216%
At each fiscal year end
Single quarter
Free cash flow, TTM
-$93.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM QSI
FY Dec 2025
-$97.2M
FY Dec 2024
-$92.4M
FY Dec 2023
-$98.5M
FY Dec 2022
-$101.3M
FY Dec 2021
-$72.6M
Jun 2026
-$18.5M
Mar 2026
-$25.9M
Dec 2025
-$16.3M
Sep 2025
-$32.9M
Jun 2025
-$20.5M
Mar 2025
-$27.5M
Dec 2024
-$24.3M
Sep 2024
-$24.1M
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity QSI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt QSI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-49.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity QSI
FY Dec 2025
-46.5%
FY Dec 2024
-41.5%
FY Dec 2023
-30.4%
FY Dec 2022
-31.7%
FY Dec 2021
-59.9%
Jun 2026
-49.1%
Mar 2026
-46.4%
Dec 2025
-46.5%
Sep 2025
-52.4%
Jun 2025
-46.9%
Mar 2025
-40.2%
Dec 2024
-41.5%
Sep 2024
-35.8%
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-44.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets QSI
FY Dec 2025
-41.1%
FY Dec 2024
-37.0%
FY Dec 2023
-27.8%
FY Dec 2022
-29.6%
FY Dec 2021
-34.9%
Jun 2026
-44.0%
Mar 2026
-42.9%
Dec 2025
-41.1%
Sep 2025
-47.1%
Jun 2025
-41.7%
Mar 2025
-36.8%
Dec 2024
-37.0%
Sep 2024
-32.4%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital QSI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-53.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed QSI
FY Dec 2025
-51.3%
FY Dec 2024
-42.1%
FY Dec 2023
-33.6%
FY Dec 2022
-28.6%
FY Dec 2021
-36.6%
Jun 2026
-53.7%
Mar 2026
-49.9%
Dec 2025
-51.3%
Sep 2025
-54.8%
Jun 2025
-47.9%
Mar 2025
-41.9%
Dec 2024
-42.1%
Sep 2024
-40.1%
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing QSI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no share count filed
Enterprise value QSI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
no share count filed
FCF yield QSI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing QSI
FY Dec 2025
n/a
FY Dec 2024
n/a
FY Dec 2023
n/a
FY Dec 2022
n/a
FY Dec 2021
n/a
Jun 2026
n/a
Mar 2026
n/a
Dec 2025
n/a
Sep 2025
n/a
Jun 2025
n/a
Mar 2025
n/a
Dec 2024
n/a
Sep 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
QSI ranks highest on risk and compliance (55th percentile) and insider conviction (36th), and lowest on growth (7th), among Industrials peers.
Profitability
11
Inputs
Return on equity-49.1% · 12 pct, sector of 198
Return on assets-44.0% · 11 pct, sector of 224
Return on invested capitalpre-tax loss, no effective tax rate to apply
Return on capital employed-53.7% · 9 pct, sector of 195
Growth
7
Inputs
Revenue growth, YoY-20.3% · 7 pct, sector of 255
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
36
Inputs
Net Form 4 buying (codes P and S), 180d-$111K · 72 pct, sector of 171
Insider buyers, 180d0 · 0 pct, sector of 173
Institutional and government
26
Inputs
Funds adding, latest quarter64 · 26 pct, sector of 200
Congress net buyers, 365dno Congress trades in 365 days
Federal contracts, 180dno federal contracts in 180 days
Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
55
Inputs
Short interest, % of float+7.3% · 26 pct, sector of 271
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-K+5.7% · 84 pct, sector of 197
2 not measured: Financial health, US patents
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
QSI filings, in plain words
Are Quantum-Si insiders buying or selling QSI?
In the 180 days to 2026-10-28, Quantum-Si insiders were net sellers, a net $110.7K across purchases and sales reported on Form 4, by 4 sellers.
Are there planned insider sales of QSI?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $39.4K of stock; the latest, by Hawkins Jeffrey Alan, was filed 2026-09-23.
Read the full summary
In the 180 days to 2026-10-28, Quantum-Si insiders were net sellers of QSI, a net $110.7K across purchases and sales reported on Form 4 by 4 sellers. None of the 14 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $39.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.